Tolemy Bio detailed its path to a €1.54 million pre-seed raise, framing the financing as tied to a pivot toward software for converting biological data into forms usable by AI systems. The company’s Orbit platform emerged from customer conversations after founders stepped back from public fundraising during a deliberately quiet period. The interview emphasizes how a manufacturing deal and customer evidence shaped investor discussions, and it positions the company’s commercial narrative around a platform strategy rather than services alone. For the sector, the round is a data point on continued funding for AI-native biology infrastructure tied to deployable workflows.